Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription

Nephrology Dialysis Transplantation

Volumn 25, Issue 5, 2010, Pages 1633-1638

  Habib, Anne Marie ^a   Preston, Emma ^a   Davenport, Andrew ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Encapsulating peritoneal sclerosis; Glucose; Icodextrin; Peritoneal dialysis

Indexed keywords

CREATININE; ICODEXTRIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENCAPSULATING PERITONEAL SCLEROSIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; PERITONEAL DIALYSIS; PERITONITIS; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SCLEROSIS; ULTRAFILTRATION;

ADULT; AGED; FEMALE; GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; RISK FACTORS;

EID: 77951696797     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp677     Document Type: Article

References (23)

1. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002-2003. Perit Dial Int 2009; 29: 297-302
2. Gandhi VC, Humayan HM, Ing TS. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140: 1201-1203 (Pubitemid 10048816)
3. Kawanishi H, Kawaguchi Y, Fukui H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective controlled, multicenter study. Am J Kidney Dis 2004; 44: 729-737 (Pubitemid 39237618)
4. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159
5. Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009
6. Yamamoto R, Nakayama M, Hasegawa T, et al. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18: 131-134
7. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3: 66-69
8. Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Disease 1996; 28: 420-427 (Pubitemid 26304423)
9. Brown MC, Simpson K, Kerssens JJ, et al. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4: 1222-1229
10. Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibrium test. Perit Dial Bull 1987; 7: 138-147
11. Willicombe MK, Davenport A. Hydration status does not influence peritoneal equilibration test ultrafiltration volumes. Clin J Am Soc Nephrol 2009; 4: 1207-1211
12. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005; 25: S14-S18 (Pubitemid 41600355)
13. Korte MR, Yo M, Betjes MG, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Ne-phrol Dial Transplant 2007; 22: 2412-2414 (Pubitemid 47244739)
14. Hendriks PM, Ho-dac-Pannekeet MM, van Gulik TM, et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136-143
15. Lo WK, Chan KT, Leung AC, et al. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlor-hexidine in alcohol. Adv Perit Dial 1990; 6: 79-84
16. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25: S48-S56 (Pubitemid 41600359)
17. Yamamoto R, Otsuka Y, Nakayama M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005; 92: 148-152 (Pubitemid 40875105)
18. Davies SJ, Woodrow G, Donovan K, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-2344 (Pubitemid 37052381)
19. Davies SJ, Brown EA, Frandsen NE, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609-1615
20. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888-893
21. Davies SJ, Phillips L, Naish PF, et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051 (Pubitemid 32378346)
22. Wilkie ME, Plant MJ, Edwards L, et al. Icodextrin 7. 5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17: 84-87 (Pubitemid 27475054)
23. Kawaguchi Y, Saito A, Kawanishi H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25: S83-S95 (Pubitemid 41600364)